2. Academic Validation
  3. Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors

Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors

  • Bioorg Med Chem. 2013 Nov 1;21(21):6804-20. doi: 10.1016/j.bmc.2013.07.032.
Dengyou Zhang 1,  Xiaowei Zhang,  Jing Ai,  Yun Zhai,  Zhongjie Liang,  Ying Wang,  Yi Chen,  Chunpu Li,  Fei Zhao,  Hualiang Jiang,  Meiyu Geng,  Cheng Luo,  Hong Liu
Affiliations

Affiliation

  • 1 State Key Laboratory of Drug Research, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, PR China.
PMID: 23993328 DOI: 10.1016/j.bmc.2013.07.032
Abstract

A series of 2-amino-N-benzylpyridine-3-carboxnamides, 2-amino-N-benzylpyridine-3-sulfonamides and 2-amino-3-benzylthiopyridines against c-Met were designed by means of bioisosteric replacement and docking analysis. Optimization of the 2-amino-3-benzylthiopyridine scaffold led to the identification of compound (R)-10b displaying c-Met inhibition with an IC50 up to 7.7nM. In the cytotoxic evaluation, compound (R)-10b effectively inhibited the proliferation of c-Met addictive human Cancer cell lines (IC50 from 0.19 to 0.71μM) and c-Met activation-mediated cell metastasis. At a dose of 100mg/Kg, (R)-10b evidently inhibited tumor growth (45%) in NIH-3T3/TPR-Met xenograft model. Of note, (R)-10b could overcome c-Met-activation mediated gefitinib-resistance, which indicated its potential use for drug combination. Taken together, 2-amino-3-benzylthiopyridine scaffold was first disclosed and exhibited promising pharmacological profiles against c-Met, which left room for further exploration.

Keywords

2-Amino-5-aryl-3-benzylthiopyridine; Receptor tyrosine kinase; c-Met.

Figures